The potential of photodynamic therapy (PDT)—Experimental investigations and clinical use

Oniszczuk, Anna; Wojtunik-Kulesza, Karolina; Oniszczuk, Tomasz; Kasprzak, Kamila

doi:10.1016/j.biopha.2016.07.058

Cited by 179 publications

(135 citation statements)

References 138 publications

Supporting

Mentioning

114

Contrasting

Unclassified

Order By: Relevance

“…PDT is already an established treatment modality for dysplastic Barrett’s epithelium [23]. It has also shown utility in the treatment of cancers of the prostate, lung, pancreas, bile duct, oral cavity and skin [24, 25]. PDT involves the administration of a photosensitizer (PS) and its activation locally using light to cause cellular destruction via intracellular free radicals and/or reactive oxygen species [26–29].…”

Section: Introductionmentioning

confidence: 99%

Upregulation of mucin glycoprotein MUC1 in the progression to esophageal adenocarcinoma and therapeutic potential with a targeted photoactive antibody-drug conjugate

et al. 2017

View full text Add to dashboard Cite

BackgroundMucin glycoprotein 1 (MUC1) is a glycosylated transmembrane protein on epithelial cells. We investigate MUC1 as a therapeutic target in Barrett’s epithelium (BE) and esophageal adenocarcinoma (EA) and provide proof of concept for a light based therapy targeting MUC1.RESULTSMUC1 was present in 21% and 30% of significantly enriched pathways comparing BE and EA to squamous epithelium respectively. MUC1 gene expression was x2.3 and x2.2 higher in BE (p=<0.001) and EA (p=0.03). MUC1 immunohistochemical expression increased during progression to EA and followed tumor invasion. HuHMFG1 based photosensitive antibody drug conjugates (ADC) showed cell internalization, MUC1 selective and light-dependent cytotoxicity (p=0.0006) and superior toxicity over photosensitizer alone (p=0.0022).MethodsGene set enrichment analysis (GSEA) evaluated pathways during BE and EA development and quantified MUC1 gene expression. Immunohistochemistry and flow cytometry evaluated the anti-MUC1 antibody HuHMFG1 in esophageal cells of varying pathological grade. Confocal microscopy examined HuHMFG1 internalization and HuHMFG1 ADCs were created to deliver a MUC1 targeted phototoxic payload.ConclusionsMUC1 is a promising target in EA. Molecular and light based targeting of MUC1 with a photosensitive ADC is effective in vitro and after development may enable treatment of locoregional tumors endoscopically.

show abstract

Section: Introductionmentioning

confidence: 99%

Upregulation of mucin glycoprotein MUC1 in the progression to esophageal adenocarcinoma and therapeutic potential with a targeted photoactive antibody-drug conjugate

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The aggregation properties of a photosensitizer in studied media may affect its photochemical and photophysical properties. So, aggregation studies were carried out for compounds (4)(5)(6) in solution. Firstly, the 1.00 × 10 À 5 M solutions of (4-6) were investigated in different solvents.…”

Section: Aggregation Studiesmentioning

confidence: 99%

“…[37][38][39] When the compound (5) compared with Std-ZnPc the result showed that substituted groups on the phthalocyanine increased the fluorescence quantum yield. When the compound (4) compared with compound (5) the result showed that zinc(II) ion increased fluorescence quantum yield (Figure 4, as an example for compound (5)).…”

Section: Chemistryselectmentioning

confidence: 99%

See 1 more Smart Citation

Synthesis, Characterization, Photophysical and Photochemical Properties of Novel Phthalocyanines

Demirbaş

2020

ChemistrySelect

View full text Add to dashboard Cite

The benzothiazole substituted phthalonitrile (3) and nonperipherally tetra benzothiazole substituted metal-free (4), zinc (II) (5) and lead(II) phthalocyanine (6) complexes were prepared. The compounds (3-6) were characterized by IR, NMR, UV-Vis and mass spectroscopy data. After synthesis, photochemical and photophysical parameters of the compounds (4-6) were analyzed to determine photosensitizer performance of them for PDT applications. Firstly, the most suitable solvent for compounds (4-6) was found by aggregation studies. Then, fluorescence properties were measured in DMF at 1x10 À 6 M. Singlet oxygen properties were measured in DMF by using 1,3diphenylisobenzofuran (DPBF) as a singlet oxygen quencher. Photodegradation properties were measured under light irradiation in DMF at 1x10 À 5 M. The zinc(II) phthalocyanine (5) had the highest singlet oxygen production capacity (Φ~= 0.62), fluorescence (Φ F = 0.25) and photodegradation quantum yield (Φ d = 3.28x10-4). The results showed that zinc(II) phthalocyanine (5) has potential for photodynamic therapy applications.

show abstract

“…Type II reactions contribute to the activation of the oxygen molecule directly. Then, singlet oxygen, the core of the reaction, is produced from the transfer of electrons to O 2 , which causes cell injury in the tumor (Figure 1) [29, 30]. At the meantime, 1 O 2 will react with substrates or solvents and enhancing Type I reactions induced by ROS.…”

Section: Oxidative Stressmentioning

confidence: 99%

A review and outlook in the treatment of osteosarcoma and other deep tumors with photodynamic therapy: from basic to deep

Zhu

Wang

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Photodynamic therapy, one of the most promising minimally invasive treatments, has received increasing focus in tumor therapy research, which has been widely applied in treating superficial tumors. Three basic factors - photosensitizer, the light source, and oxidative stress - are responsible for tumor cell cytotoxicity. However, due to insufficient luminous flux and peripheral tissue damage, the utilization of photodynamic therapy is facing a huge limitation in deep tumor therapy. Osteosarcoma is the typical deep tumor, which is the most commonly occurring malignancy in children and adolescents. Despite developments in surgery, high risks of the amputation still threatens the health of osteosarcoma patients. In this review, we summarize recent developments in the field of photodynamic therapy and specifically PDT research in OS treatment modalities. In addition, we also provide some novel suggestions, which could potentially be a breakthrough in PDT-induced OS therapies. PDT has the potential to become an effective therapy while the its limitations still present when applied on the treatment of OS or other types of deep tumors. Thus, more researches and studies in the field are required.

show abstract

The potential of photodynamic therapy (PDT)—Experimental investigations and clinical use

Cited by 179 publications

References 138 publications

Upregulation of mucin glycoprotein MUC1 in the progression to esophageal adenocarcinoma and therapeutic potential with a targeted photoactive antibody-drug conjugate

Upregulation of mucin glycoprotein MUC1 in the progression to esophageal adenocarcinoma and therapeutic potential with a targeted photoactive antibody-drug conjugate

Synthesis, Characterization, Photophysical and Photochemical Properties of Novel Phthalocyanines

A review and outlook in the treatment of osteosarcoma and other deep tumors with photodynamic therapy: from basic to deep

Contact Info

Product

Resources

About